900 related articles for article (PubMed ID: 27865762)
21. Soft matter assemblies as nanomedicine platforms for cancer chemotherapy: a journey from market products towards novel approaches.
Jäger E; Giacomelli FC
Curr Top Med Chem; 2015; 15(4):328-44. PubMed ID: 25633209
[TBL] [Abstract][Full Text] [Related]
22. Drug targeting to tumors: principles, pitfalls and (pre-) clinical progress.
Lammers T; Kiessling F; Hennink WE; Storm G
J Control Release; 2012 Jul; 161(2):175-87. PubMed ID: 21945285
[TBL] [Abstract][Full Text] [Related]
23. Recent Advances in Targeted Tumor Chemotherapy Based on Smart Nanomedicines.
Qin SY; Zhang AQ; Zhang XZ
Small; 2018 Nov; 14(45):e1802417. PubMed ID: 30247806
[TBL] [Abstract][Full Text] [Related]
24. Reappraisal of anticancer nanomedicine design criteria in three types of preclinical cancer models for better clinical translation.
Luan X; Yuan H; Song Y; Hu H; Wen B; He M; Zhang H; Li Y; Li F; Shu P; Burnett JP; Truchan N; Palmisano M; Pai MP; Zhou S; Gao W; Sun D
Biomaterials; 2021 Aug; 275():120910. PubMed ID: 34144373
[TBL] [Abstract][Full Text] [Related]
25. Tumor Abnormality-Oriented Nanomedicine Design.
Zhou Q; Xiang J; Qiu N; Wang Y; Piao Y; Shao S; Tang J; Zhou Z; Shen Y
Chem Rev; 2023 Sep; 123(18):10920-10989. PubMed ID: 37713432
[TBL] [Abstract][Full Text] [Related]
26. Cancer Nanotheranostics: A Nanomedicinal Approach for Cancer Therapy and Diagnosis.
Kundu P; Singh D; Singh A; Sahoo SK
Anticancer Agents Med Chem; 2020; 20(11):1288-1299. PubMed ID: 31429694
[TBL] [Abstract][Full Text] [Related]
27. Nanomedicines for the treatment of hematological malignancies.
Deshantri AK; Varela Moreira A; Ecker V; Mandhane SN; Schiffelers RM; Buchner M; Fens MHAM
J Control Release; 2018 Oct; 287():194-215. PubMed ID: 30165140
[TBL] [Abstract][Full Text] [Related]
28. Factors affecting toxicity and efficacy of polymeric nanomedicines.
Igarashi E
Toxicol Appl Pharmacol; 2008 May; 229(1):121-34. PubMed ID: 18355886
[TBL] [Abstract][Full Text] [Related]
29. Nanomedicine formulations for the delivery of antiviral drugs: a promising solution for the treatment of viral infections.
Lembo D; Donalisio M; Civra A; Argenziano M; Cavalli R
Expert Opin Drug Deliv; 2018 Jan; 15(1):93-114. PubMed ID: 28749739
[TBL] [Abstract][Full Text] [Related]
30. Multifunctional nanoparticles for use in theranostic applications.
Cole JT; Holland NB
Drug Deliv Transl Res; 2015 Jun; 5(3):295-309. PubMed ID: 25787729
[TBL] [Abstract][Full Text] [Related]
31. Theranostic Nanomedicine; A Next Generation Platform for Cancer Diagnosis and Therapy.
Sharma R; Mody N; Agrawal U; Vyas SP
Mini Rev Med Chem; 2017; 17(18):1746-1757. PubMed ID: 26891932
[TBL] [Abstract][Full Text] [Related]
32. Advances in Functionalized Mesoporous Silica Nanoparticles for Tumor Targeted Drug Delivery and Theranostics.
Zhang W; Liu M; Liu A; Zhai G
Curr Pharm Des; 2017; 23(23):3367-3382. PubMed ID: 27784244
[TBL] [Abstract][Full Text] [Related]
33. New Strategies in Cancer Nanomedicine.
Tong R; Kohane DS
Annu Rev Pharmacol Toxicol; 2016; 56():41-57. PubMed ID: 26514197
[TBL] [Abstract][Full Text] [Related]
34. Factors Influencing the Delivery Efficiency of Cancer Nanomedicines.
Ullah R; Wazir J; Khan FU; Diallo MT; Ihsan AU; Mikrani R; Aquib M; Zhou X
AAPS PharmSciTech; 2020 May; 21(4):132. PubMed ID: 32409932
[TBL] [Abstract][Full Text] [Related]
35. Tumor-Targeted Nanomedicine for Immunotherapy.
Cabral H; Kinoh H; Kataoka K
Acc Chem Res; 2020 Dec; 53(12):2765-2776. PubMed ID: 33161717
[TBL] [Abstract][Full Text] [Related]
36. Theranostics of metal-organic frameworks: image-guided nanomedicine for clinical translation.
Mehata AK; Vikas ; Viswanadh MK; Muthu MS
Nanomedicine (Lond); 2023 Apr; 18(8):695-703. PubMed ID: 37259854
[TBL] [Abstract][Full Text] [Related]
37. Challenging the fundamental conjectures in nanoparticle drug delivery for chemotherapy treatment of solid cancers.
Yang J; Wang X; Wang B; Park K; Wooley K; Zhang S
Adv Drug Deliv Rev; 2022 Nov; 190():114525. PubMed ID: 36100142
[TBL] [Abstract][Full Text] [Related]
38. Nanomedicines as cancer therapeutics: current status.
Akhter S; Ahmad I; Ahmad MZ; Ramazani F; Singh A; Rahman Z; Ahmad FJ; Storm G; Kok RJ
Curr Cancer Drug Targets; 2013 May; 13(4):362-78. PubMed ID: 23517593
[TBL] [Abstract][Full Text] [Related]
39. Engineering Nanomedicines to Overcome Multidrug Resistance in Cancer Therapy.
Beretta GL; Cavalieri F
Curr Med Chem; 2016; 23(1):3-22. PubMed ID: 26438248
[TBL] [Abstract][Full Text] [Related]
40. Development of next generation nanomedicine-based approaches for the treatment of cancer: we've barely scratched the surface.
Tracey SR; Smyth P; Barelle CJ; Scott CJ
Biochem Soc Trans; 2021 Nov; 49(5):2253-2269. PubMed ID: 34709394
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]